# Oncternal Therapeutics Inc. (ONCT)

Source: https://www.quantisnow.com/company/ONCT
Generated: 2026-11-14T15:41:35.416Z

- Ticker: ONCT
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2004
- Website: oncternal.com

## About

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical need. Its pipeline includes cirmtuzumab, an investigational monoclonal antibody that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including mantle cell lymphoma and chronic lymphocytic leukemia. The company also develops a chimeric antigen receptor T cell therapy that targets Receptor tyrosine kinase-like Orphan Receptor 1, which is in preclinical development as a potential treatment for hematologic cancers and solid tumors. In addition, it is developing TK216, an investigational small molecule that inhibits the E26 Transformation Specific family of oncoproteins. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; Shanghai Pharmaceutical (USA) Inc.; Selexis S.A.; and University of Tennessee Research Foundation. The company is headquartered in San Diego, California.

## Latest ONCT news and filings

- 2026-06-23 12:30 UTC [Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board](https://www.quantisnow.com/insight/alpha-cognition-announces-election-of-dr-robert-wills-as-chairman-6611994)
- 2025-07-01 12:00 UTC [Mergers & Acquisitions] [Oncternal Therapeutics Announces the Sale of Select Development Programs and the Wind-Down of its Operations](https://www.quantisnow.com/insight/oncternal-therapeutics-announces-the-sale-of-select-development-programs-and-6104811)
- 2025-04-10 12:30 UTC [Leadership Update] [Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens](https://www.quantisnow.com/insight/alpha-cognition-strengthens-its-leadership-team-with-appointment-of-robert-5983746)
- 2025-03-07 21:05 UTC [Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC](https://www.quantisnow.com/insight/oncternal-therapeutics-announces-intent-to-voluntarily-delist-from-nasdaq-and-5933238)
- 2024-11-25 11:03 UTC [SEC Form 8-K] [Oncternal Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/oncternal-therapeutics-inc-filed-sec-form-8-k-notice-of-delisting-5789296)
- 2024-11-14 22:08 UTC [SEC Form 8-K] [Oncternal Therapeutics Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Leadership Update](https://www.quantisnow.com/insight/oncternal-therapeutics-inc-filed-sec-form-8-k-costs-associated-with-5776983)
- 2024-11-06 21:30 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Oncternal Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-oncternal-therapeutics-inc-5756197)
- 2024-10-22 13:00 UTC [Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer](https://www.quantisnow.com/insight/oncternal-therapeutics-announces-updated-safety-and-efficacy-data-for-phase-5732864)
- 2024-09-12 20:49 UTC [SEC Form 8-K] [Oncternal Therapeutics Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Leadership Update, Other Events](https://www.quantisnow.com/insight/oncternal-therapeutics-inc-filed-sec-form-8-k-costs-associated-with-5692379)
- 2024-09-12 13:00 UTC [Oncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives](https://www.quantisnow.com/insight/oncternal-therapeutics-announces-termination-of-its-clinical-studies-and-exploration-5691564)
- 2024-08-08 20:30 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Oncternal Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-oncternal-therapeutics-inc-5651163)
- 2024-08-08 20:10 UTC [SEC Form 8-K] [Oncternal Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/oncternal-therapeutics-inc-filed-sec-form-8-k-results-of-operations-5650642)
- 2024-08-08 20:01 UTC [Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results](https://www.quantisnow.com/insight/oncternal-therapeutics-provides-business-update-and-announces-second-quarter-2024-5650132)
- 2024-08-01 20:05 UTC [Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results](https://www.quantisnow.com/insight/oncternal-therapeutics-to-provide-business-update-and-report-second-quarter-5637974)
- 2024-07-16 11:53 UTC [Market Chatter] [HC Wainwright & Co. Reiterates Buy on Oncternal Therapeutics, Maintains $19 Price Target](https://www.quantisnow.com/insight/hc-wainwright-co-reiterates-buy-on-oncternal-therapeutics-maintains-19-5609559)
- 2024-07-15 12:08 UTC [Market Chatter] [Oncternal Therapeutics Completes Enrollment And Begins Dosing For Sixth Dose Cohort In Phase 1/2 Study Of ONCT-534 For Metastatic Castration-Resistant Prostate Cancer](https://www.quantisnow.com/insight/oncternal-therapeutics-completes-enrollment-and-begins-dosing-for-sixth-dose-5607444)
- 2024-07-15 12:00 UTC [Oncternal Announces Enrollment Completed and Dosing Initiated for Sixth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer](https://www.quantisnow.com/insight/oncternal-announces-enrollment-completed-and-dosing-initiated-for-sixth-dose-5607367)
- 2024-07-11 20:05 UTC [Conference Announcement] [Oncternal Therapeutics to Present in JonesTrading Healthcare Summit](https://www.quantisnow.com/insight/oncternal-therapeutics-to-present-in-jonestrading-healthcare-summit-5604425)
- 2024-06-24 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Director Kisner Daniel L](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-kisner-daniel-l-5573650)
- 2024-06-24 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Director Carter Michael G](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-carter-michael-g-5573642)
- 2024-06-24 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Director Larue William R](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-larue-william-r-5573630)
- 2024-06-24 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Director Desimone Jill](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-desimone-jill-5573629)
- 2024-06-24 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Director Theuer Charles](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-theuer-charles-5573626)
- 2024-06-24 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Director Hale David F](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-hale-david-f-5573625)
- 2024-06-24 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Director Wills Robert James](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-wills-robert-james-5573623)
- 2024-06-24 20:05 UTC [SEC Form 4] [SEC Form 4 filed by Director Mazanet Rosemary](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-mazanet-rosemary-5573622)
- 2024-06-21 20:05 UTC [SEC Form 8-K] [Oncternal Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/oncternal-therapeutics-inc-filed-sec-form-8-k-submission-of-matters-5570994)
- 2024-05-31 10:12 UTC [Market Chatter] [HC Wainwright & Co. Reiterates Buy on Oncternal Therapeutics, Maintains $19 Price Target](https://www.quantisnow.com/insight/hc-wainwright-co-reiterates-buy-on-oncternal-therapeutics-maintains-19-5527728)
- 2024-05-30 20:45 UTC [Market Chatter] [Oncternal Completes Enrollment And Dosing Initiated For 5th Dose Cohort Of Phase 1/2 Study Of ONCT-534 For The Treatment Of R/R Metastatic Castration-Resistant Prostate Cancer](https://www.quantisnow.com/insight/oncternal-completes-enrollment-and-dosing-initiated-for-5th-dose-cohort-5526946)
- 2024-05-30 20:05 UTC [Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer](https://www.quantisnow.com/insight/oncternal-announces-enrollment-completed-and-dosing-initiated-for-fifth-dose-5526239)
- 2024-05-13 12:01 UTC [Market Chatter] [HC Wainwright & Co. Maintains Buy on Oncternal Therapeutics, Lowers Price Target to $19](https://www.quantisnow.com/insight/hc-wainwright-co-maintains-buy-on-oncternal-therapeutics-lowers-price-5483692)
- 2024-05-09 20:22 UTC [Market Chatter] [Oncternal Therapeutics Q1 2024 GAAP EPS $(2.83) Beats $(2.88) Estimate, Sales $569.000K Beat $176.667K Estimate](https://www.quantisnow.com/insight/oncternal-therapeutics-q1-2024-gaap-eps-283-beats-288-estimate-5478121)
- 2024-05-09 20:17 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Oncternal Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-oncternal-therapeutics-inc-5478007)
- 2024-05-09 20:05 UTC [SEC Form 8-K] [Oncternal Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/oncternal-therapeutics-inc-filed-sec-form-8-k-results-of-operations-5477485)
- 2024-05-09 20:01 UTC [Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results](https://www.quantisnow.com/insight/oncternal-therapeutics-provides-business-update-and-announces-first-quarter-2024-5477126)
- 2024-05-02 20:05 UTC [Oncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial Results](https://www.quantisnow.com/insight/oncternal-therapeutics-to-provide-business-update-and-report-first-quarter-5454306)
- 2024-05-02 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Oncternal Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-oncternal-therapeutics-inc-5451229)
- 2024-05-01 13:00 UTC [Leadership Update] [Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)](https://www.quantisnow.com/insight/oncternal-therapeutics-reports-inducement-award-under-nasdaq-listing-rule-5635c4-5447944)
- 2024-04-26 20:17 UTC [SEC Form ARS filed by Oncternal Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-ars-filed-by-oncternal-therapeutics-inc-5437730)
- 2024-04-26 20:15 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Oncternal Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-oncternal-therapeutics-inc-5437683)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ONCT
- Earnings history: https://www.quantisnow.com/earnings/ONCT
- Dividend history: https://www.quantisnow.com/dividends/ONCT
- Insider transactions: https://www.quantisnow.com/insiders/ONCT
- Options chain: https://www.quantisnow.com/options/ONCT
- SEC 8-K filings only: https://www.quantisnow.com/company/ONCT/8-k
- RSS and alerts for ONCT: https://www.quantisnow.com/docs/rss-feeds.md